EMEA-001911-PIP01-15-M04
Key facts
| Invented name |
Uplizna
|
| Active substance |
Inebilizumab
|
| Therapeutic area |
Neurology
|
| Decision number |
P/0213/2022
|
| PIP number |
EMEA-001911-PIP01-15-M04
|
| Pharmaceutical form(s) |
|
| Condition(s) / indication(s) |
Treatment of neuromyelitis optica spectrum disorders
|
| Route(s) of administration |
Intravenous use
|
| Contact for public enquiries |
Horizon Therapeutics Ireland DAC
E-mail: customerservice@horizontherapeutics.com |
| Decision type |
PM: decision on the application for modification of an agreed PIP
|